patrys

Annual General Meeting 2016

Dr James Campbell CEO

Safe harbour statement

The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Patrys nor any other entity or person in or associated with the Patrys group of companies guarantees any return (whether capital or income) or generally the performance of Patrys or the price at which its securities may trade.

In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Patrys securities. It is not for general distribution or third party reliance or use. While it has been prepared from sources Patrys believe to be reliable, Patrys cannot guarantee its accuracy or completeness and undertakes no obligation to advise of changes or updates to any such materials.

These materials are not exhaustive of all of the information a potential investor or their professional adviser would require. Nor do these materials take into account any specific objectives, financial situation or needs of investors. In addition, the past performance of Patrys cannot be assumed as indicative of the future performance of the company. For these and other reasons, before making any investment decision regarding Patrys securities you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Where this presentation does contain any forward looking statements, those statements are only made as the date of the presentation and are to be considered “at-risk statements” not to be relied upon as they are subject to further research and to known and unknown risks, uncertainties and other factors that may lead to actual results differing from any forward looking statement. This is particularly the case with companies such as Patrys which operate in the field of researching, discovering, developing, and commercialising potential drugs intended for safe and effective for human treatments or therapies.

Vision

Patrys is a biopharmaceutical company devoted to the development and commercialisation of novel antibody technologies to improve the clinical outcomes for cancer patients

Snapshot

Exciting antibody (Ab) platforms and pipeline	• Deoxymabs - in-licensed nuclear-penetrating Abs from Yale University • IgM platform showing safety and signals of clinical efficacy • Both platforms offer multiple opportunities for development • Ability to generate new intellectual property
Good news flow expected in 2017	• Preclinical testing of multiple Deoxymab 3E10 candidates • Lead candidate selection for Deoxymab 3E10 program • Preclinical data and publications on Abs and targets • Ongoing development of PAT-SC1 (via strategic alliance) • Additional alliances and collaborations
Good cash runway	• Strong cash position with streamlined operations and low cash burn
Proven Board and management	• Significant experience in developing anti-cancer drugs • Significant expertise in capital-raising and deal-making

Year in review

- Completed a year of restructuring, rebranding, consolidation and building
- Corporate costs reduced significantly
  - Closed German operations
  - Rationalised head office staffing
  - Migrated to technology-enabled virtual office
- IgM program progressing via alliance
  - PAT-SC1 alliance progressing on track
  - PAT-SM6 manufacturing and clinical trial remain on hold
- Deoxymab program licensed from Yale University
  - Novel, first-in-class nuclear penetrating antibodies
  - Multiple possible development paths
  - Development progressing on time and on budget

Experienced leadership team

- Board
  - John Read — Chairman
  - James Campbell — CEO & Managing Director
  - Mike Stork — Non-Executive Director
  - Suzy Jones — Non-Executive Director

- Management
  - Dr James Campbell — CEO & Managing Director
  - Melanie Leydin — CFO & Company Secretary
  - Dr Deanne Greenwood — VP, Business Development & IP
  - Valentina Dubljevic — VP, Scientific & Clinical Development

Development pipeline



IgM assets

- Patrys' IgM assets have shown anti-tumour activity in mice and in humans have shown a very good safety profile and signals of clinical efficacy



- Natural human antibodies can be combined with existing chemotherapeutic treatments potentially without any cumulative toxicology effects

- The Chinese rights for PAT-SM1 have been licensed to Hefei Co-Source, which is progressing well with its development plans. The Joint Development Committee met in October, and is pleased with progress to date. This alliance provides possible future milestone payments and royalties

- Manufacturing of PAT-SM6 and a possible clinical trial remain on hold until non-dilutive funding for this program can be obtained

- Ongoing BD efforts for all IgM assets

Introducing Deoxymab 3E10

- Deoxymab 3E10 is a nuclear-penetrating lupus anti-DNA autoantibody with proven utility as a molecular delivery vehicle
- 3E10 has previously been used in Phase 1 clinical trial for lupus
- Anti-cancer application licensed from Yale University
- First in class mechanism of action – potentially major advantages over PARP inhibitors
- Patrys is developing di-scFv to target solid tumors, particularly glioblastoma, pancreatic, breast and ovarian

Deoxymab 3E10 – Mechanism of action



Research partnered with Yale University

- James E. Hansen, MD (Principal Investigator)
  - Assistant Professor, Department of Therapeutic Radiology, Yale School of Medicine
  - Physician-scientist and practicing radiation oncologist specializing in treatment of cancers of the brain, head and neck, lung, skin, and lymphatic system
  - 12+ years of experience working with 3E10 and other cell-penetrating Abs
  - Lead inventor on patents pertaining to use of Deoxymabs against cancer

- Jiangbing Zhou, PhD (Collaborator)
  - Assistant Professor, Department of Neuro-surgery and Biomedical Engineering, Yale School of Medicine
  - Expert in animal models for drug candidate testing, with special expertise in brain tumor models

Multiple development paths for 3E10



Deoxymab 3E10



Combination with radiation therapy for radioresistant tumors and/or to reduce the required dose of radiation

Single agent for targeted therapy of malignancies with defects in DNA repair, such as BRCA or PTEN-deficient cancers

Combination with chemotherapy for chemo-resistant tumors and/ or to reduce the required dose of chemotherapy

Deoxymab 3E10 enhances radiotherapy

3E10 scFv radiosensitises U87 human glioma cells, but is not toxic to unirradiated cells



Hansen *et al.*, (2012) *Science Translational Medicine*, 4(157): 157ra142.

Deoxymab 3E10 enhances chemotherapy

Using U87 human glioma cells Deoxymab 3E10 enhances chemotherapy which causes DNA damage (Doxorubicin), but not chemotherapy that doesn't affect DNA (Paclitaxel)



Hansen *et al.*, (2012) *Science Translational Medicine*, 4(157): 157ra142.

Deoxymab 3E10 single agent efficacy

Deoxymab 3E10 decreases tumour growth in BRCA2-deficient CAPAN-1(pancreatic) xenografts



Noble *et al.* (2015). *Cancer Research*. 75(11): 2285-91.

Deoxymab 3E10 development milestones



The year ahead

- Completion of *in silico* design and optimization of Deoxymab 3E10 ✓
- Preclinical testing of multiple Deoxymab 3E10 candidates ✓
- Lead candidate selection for Deoxymab 3E10 program
- Preclinical data and publications on Abs and targets
- Ongoing development of PAT-SC1 (via strategic alliance)
- Additional alliances and collaborations

Further information

Dr James Campbell, CEO and Managing Director

Ph: +61 3 9670 3273

Email: info@patrys.com

Website: www.patrys.com